Project 461155
Exploring the therapeutic potential of combined inhibition of MNK1/2 and CDK4/6 to treat melanoma.
Exploring the therapeutic potential of combined inhibition of MNK1/2 and CDK4/6 to treat melanoma.
Project Information
| Study Type: | Unclear |
| Research Theme: | Biomedical |
Institution & Funding
| Principal Investigator(s): | Miller, Wilson H |
| Co-Investigator(s): | Del Rincon, Sonia V |
| Institution: | Lady Davis Institute for Medical Research (Mtl) |
| CIHR Institute: | Cancer Research |
| Program: | |
| Peer Review Committee: | Cancer Biology & Therapeutics |
| Competition Year: | 2022 |
| Term: | 5 yrs 0 mth |
Abstract Summary
Drugs that activate the immune system have provided dramatic improvements in response and overall survival to a growing number of deadly malignancies. Unfortunately, these therapies do not work in all patients. We have studied how small molecules that inhibit intracellular signaling can work in combination to block skin cancer, even in those with genetic mutations for which current therapies are lacking. In this application, we propose to test how such inhibitors can increase anti-tumor activity. We anticipate this work to lead to the development of new treatments for patients with skin cancer, but also for other tumor types where some of these small molecule drugs are being used as standard of care therapy.
No special research characteristics identified
This project does not include any of the advanced research characteristics tracked in our database.